SCHEMBL4455276

SCHEMBL4455276

CC(=O)Nc1cccc2c(S(=O)(=O)NCCc3ccccc3)cccc12

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NSD2 O96028 4/20 0.62
ALDH1A1 P00352 2/20 0.57
KMT2A Q03164 2/20 0.57
MEN1 O00255 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
EDNRA P25101 1/20 0.52
CCR8 P51685 1/20 0.51
KDM4E B2RXH2 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C9 P11712 1/20 0.51
MAPK1 P28482 1/20 0.51
CYP2C19 P33261 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
USP30 Q70CQ3 1/20 0.49
NPY5R Q15761 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.47
PIK3C3 Q8NEB9 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14919628 0.84 NSD2 (0.83) NSD2ALDH1A1NPSR1KDM4ECYP1A2
SCHEMBL23092875 0.82 EDNRA (0.55) NSD2ALDH1A1KMT2AMEN1EDNRA
SCHEMBL29900505 0.82 EDNRA (0.55) NSD2ALDH1A1KMT2AMEN1EDNRA
SCHEMBL4446946 0.81 CCR8 (0.58) NSD2KMT2AEDNRACCR8USP30
SCHEMBL4450870 0.80 EDNRA (0.48) NSD2KMT2AEDNRACCR8USP30
SCHEMBL4470111 0.79 NSD2 (0.71) NSD2ALDH1A1KMT2AMEN1NPSR1
SCHEMBL8054308 0.79 EDNRA (0.57) ALDH1A1KMT2AMEN1EDNRACCR8
SCHEMBL4443216 0.79 CCR8 (0.52) NSD2ALDH1A1EDNRACCR8USP30
SCHEMBL4444940 0.79 FABP4 (0.60) NSD2KMT2AEDNRACCR8
SCHEMBL29007374 0.78 CCR8 (0.57) CCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7547716-B2 Sulfonamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-06-16 US disclosed
EP-1402890-B1 SULFONAMIDE DERIVATIVES INST MED MOLECULAR DESIGN INC (JP) 2008-01-09 EP disclosed
US-20040234622-A1 Sulfonamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2004-11-25 US disclosed
EP-1402890-A1 SULFONAMIDE DERIVATIVES Institute of Medicinal Molecular Design, Inc. (JP) 2004-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040234622-A1 Sulfonamide derivatives PCNA, TOP2A, DDB1 NSD2 122/4885ALDH1A1 980/4885KMT2A 460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.